Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells

Cited by papers we hold 5

• CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors · 2024
  No notice
• Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets · 2022
  No notice
• Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy · 2022
  No notice
• CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy · 2021
  No notice
• Counteracting CAR T cell dysfunction · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.